Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

Sponsor

AstraZeneca (Industry)

Overall Status

Suspended

CT.gov ID

NCT00065572

Collaborator

(none)

Locations

Duration (Months)

Study Details

The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).

Condition or Disease	Intervention/Treatment	Phase
Carcinoma, Renal Cell Kidney Neoplasms	Drug: ZD6126 Drug: Placebo	Phase 2

Study Type:

Interventional

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double

Primary Purpose:

Treatment

Study Start Date :

Aug 1, 2003

Anticipated Primary Completion Date :

Feb 1, 2004

Anticipated Study Completion Date :

Feb 1, 2004

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma or within the last 3 years for any other cancer
Significant cardiac event within 3 months of entry
Any history of coronary angioplasty or history of myocardial infarction

	Site	City	State	Country
1	Research Site	Los Angeles	California	United States
2	Research Site	Newark	Delaware	United States
3	Research Site	Tampa	Florida	United States
4	Research Site	Chicago	Illinois	United States
5	Research Site	Indianapolis	Indiana	United States
6	Research Site	Baltimore	Maryland	United States
7	Research Site	St. Louis	Missouri	United States
8	Research Site	Lebanon	New Hampshire	United States
9	Research Site	Hackensack	New Jersey	United States
10	Research Site	Bronx	New York	United States
11	Research Site	Rochester	New York	United States
12	Research Site	Cleveland	Ohio	United States
13	Research Site	Portland	Oregon	United States
14	Research Site	Philadelphia	Pennsylvania	United States
15	Research Site	Nashville	Tennessee	United States
16	Research Site	Salt Lake City	Utah	United States